Skip to content

Precision oncology

TL;DR — Precision oncology in colorectal cancer is useful when a biomarker changes treatment, not merely when it is measurable. Every metastatic tumor needs MMR/MSI and extended RAS/BRAF testing; HER2 and rare fusion testing become relevant in appropriate RAS-wild-type or broad-panel pathways (Morris 2023, PMID 36252154). MSI-high/dMMR predicts large checkpoint benefit; BRAF V600E, HER2 amplification and KRAS G12C require paired pathway blockade rather than single-agent targeting (André 2020, PMID 33264544; Tabernero 2021, PMID 33503393; Strickler 2023, PMID 37142372; Fakih 2023, PMID 37870968). Primary sidedness modifies anti-EGFR benefit but is a clinical composite, not a mutation (Rossini 2023, PMID 36913832). Resistance is evolutionary: RAS/EGFR clones can emerge under anti-EGFR treatment and decay off therapy, permitting ctDNA-selected rechallenge (Parseghian 2019, PMID 30462160). Rare-target evidence is often basket or single-arm; response rate must not be confused with proven survival benefit.

Minimum metastatic biomarker set

Biomarker Method Immediate decision
MMR/MSI Four-protein IHC and/or validated MSI assay Checkpoint therapy; Lynch pathway
KRAS/NRAS exons 2–4 Tissue or validated plasma NGS Excludes anti-EGFR monotherapy strategy when mutated
BRAF V600E Tissue/plasma BRAF + EGFR combination and prognosis
HER2 amplification IHC/ISH and/or NGS with defined criteria Dual HER2 therapy in selected RAS-WT disease
NTRK/RET/ALK/ROS1 fusions RNA-capable broad assay where appropriate Rare histology-agnostic therapy
KRAS G12C NGS/PCR KRAS G12C + EGFR combination

Testing should occur early enough to affect sequence. A result returned after clinical deterioration has analytical validity but no practical utility.

Tissue versus plasma

Question Tissue strength Plasma strength
Baseline diagnosis Morphology, MMR IHC and stable drivers Fast, captures multiple sites
Low-volume disease Higher tumor content if adequate block False negatives from low shedding
Acquired resistance Requires repeat biopsy and samples one lesion Serial, multi-lesion signal
Fusion detection RNA tissue often strongest Variable assay sensitivity
Clonal hematopoiesis Less relevant Can create non-tumor variants

A negative plasma assay cannot exclude a target when shedding is low; reflex tissue testing is required if clinically important.

RAS and anti-EGFR selection

Activating KRAS or NRAS alterations predict resistance to cetuximab/panitumumab. Extended testing beyond KRAS exon 2 prevents exposure of additional resistant subgroups.

Primary side further modifies effect. Pooled randomized analyses support first-line anti-EGFR therapy primarily for left-sided RAS/BRAF-wild-type tumors; right-sided tumors favor bevacizumab-based strategies despite RAS wild type (Rossini 2023, PMID 36913832).

Feature Anti-EGFR implication
Left-sided, RAS/BRAF WT Strongest first-line survival evidence
Right-sided, RAS/BRAF WT Lower benefit; use may be reserved for response-specific contexts/later line
RAS mutation Resistant
BRAF V600E EGFR alone inadequate; pair with BRAF inhibitor
HER2 amplification Resistance mechanism; favor HER2 targeting when eligible
Acquired RAS/EGFR ectodomain alteration Resistance; may decay after withdrawal

CALGB/SWOG 80405 found median OS around 30 months with either cetuximab or bevacizumab overall, illustrating why the later side/biomarker interaction mattered (Venook 2017, PMID 28632865).

MSI-high/dMMR immunotherapy

KEYNOTE-177 reported median PFS 16.5 months with pembrolizumab versus 8.2 months with chemotherapy (HR 0.60, 95% CI 0.45–0.80) and fewer grade ≥3 treatment-related adverse events (André 2020, PMID 33264544).

CheckMate 8HW showed first-line nivolumab–ipilimumab superiority over chemotherapy and later PFS superiority over nivolumab alone (André 2024, PMID 39602630; André 2025, PMID 39874977).

Unresolved choice Benefit side Risk side
PD-1 monotherapy Lower immune toxicity Early progression in subset
PD-1 + CTLA-4 Higher response/PFS More immune adverse events
Cytotoxic bridging Rapid debulking in selected crises Lower durable control in dMMR overall

Primary resistance can arise through antigen-presentation loss, interferon-pathway disruption, immune exclusion or misclassified MMR/MSI. Previously treated KEYNOTE-164 supports durable pembrolizumab activity but also nonresponse heterogeneity (Le 2023, PMID 37141828).

BRAF V600E

BRAF V600E activates MAPK but BRAF inhibition alone fails because EGFR feedback restores signaling. Combined BRAF + EGFR blockade is therefore the mechanistic minimum.

BEACON updated analysis showed median OS 9.3 months with encorafenib–cetuximab versus 5.9 months with control (HR 0.61) and response 19.5% versus 1.8% (Tabernero 2021, PMID 33503393). Adding binimetinib did not establish a sufficient efficacy–toxicity advantage for routine triplet.

BREAKWATER moved encorafenib–cetuximab plus mFOLFOX6 first line and demonstrated superior response and PFS versus standard care (Kopetz 2025, PMID 39863775).

Adverse events span chemotherapy plus EGFR/BRAF toxicity; BEACON safety analyses provide regimen-specific management for rash, diarrhea, arthralgia and laboratory abnormalities (Tabernero 2021, PMID 34896698).

HER2-amplified disease

HER2 amplification occurs in a small, enriched subset of RAS-wild-type tumors and mediates anti-EGFR resistance. Definitions differ across IHC, ISH and NGS; copy gain without protein expression is not equivalent across assays.

HERACLES reported objective response to trastuzumab–lapatinib in heavily treated HER2-positive, KRAS-wild-type disease, proving target dependence (Sartore-Bianchi 2016, PMID 27108243).

MOUNTAINEER evaluated tucatinib–trastuzumab in chemotherapy-refractory HER2-positive, RAS-wild-type metastatic disease: confirmed objective response was 38.1% (95% CI 27.7–49.3) in cohorts A and B (Strickler 2023, PMID 37142372).

HER2 resistance can involve receptor heterogeneity, downstream RAS/PI3K alterations and loss of amplification. Rebiopsy/plasma at progression can distinguish persistent target from pathway escape.

KRAS G12C

KRAS G12C is uncommon in colorectal cancer. Single-agent G12C inhibition produces lower response than in lung cancer because EGFR feedback reactivates MAPK.

CodeBreaK 300 randomized sotorasib–panitumumab versus standard late-line therapy. The 960-mg combination improved median PFS to 5.6 versus 2.2 months (HR 0.49), with response 26.4% versus 0% (Fakih 2023, PMID 37870968).

Phase 1b data support the combination and identify rash, hypomagnesemia and diarrhea as expected toxicities (Kuboki 2024, PMID 38177853). Adagrasib–cetuximab similarly supports dual KRAS–EGFR targeting, but cross-trial comparison is not randomized evidence.

NTRK and other rare fusions

NTRK fusions are very rare and enriched in RAS/BRAF-wild-type, MSI-high or unusual tumors. Larotrectinib pooled basket trials showed high and durable response across fusion-positive solid tumors, but colorectal sample size was small (Hong 2020, PMID 32105622).

Tissue-agnostic approvals require careful assay confirmation. DNA panels can miss intronic breakpoints; RNA testing improves fusion detection. Canadian prevalence data illustrate rarity and the denominator dependence of broad screening (Silvertown 2023, PMID 36194351).

Rare RET, ALK and ROS1 fusions are investigational/targetable in selected contexts. Histology-agnostic treatment in colorectal cancer is reviewed with the caveat that most evidence pools tumor types (Sartore-Bianchi 2022, PMID 35701319).

POLE/POLD1 hypermutation

Pathogenic exonuclease-domain POLE/POLD1 alterations can create ultramutated MMR-proficient tumors with checkpoint sensitivity. Variant classification is crucial: many variants are not proofreading-deficient (Mur 2023, PMID 37848928).

Because prospective colorectal cohorts are small, treatment evidence is less mature than for MSI-high disease. Tumor mutational burden alone should not substitute for validated variant context.

Anti-EGFR resistance and rechallenge

Serial ctDNA reveals diverse acquired KRAS/NRAS, BRAF, MAP2K1, EGFR ectodomain and amplification events under anti-EGFR pressure (Topham 2023, PMID 36007218; Raghav 2023, PMID 36067452).

Parseghian and colleagues modeled exponential decay of resistant clones after withdrawal, with a cumulative half-life near 4.4 months, providing rationale for rechallenge (Parseghian 2019, PMID 30462160).

Rechallenge requirement Rationale
Prior meaningful anti-EGFR benefit Establishes baseline sensitivity
Intervening EGFR-free interval Allows resistant-clone decay
Plasma RAS/BRAF/EGFR resistance negative Enriches for renewed sensitivity
Adequate performance/skin tolerance Preserves net benefit

Japanese prospective data associated ctDNA RAS wild type at rechallenge with better outcomes, but threshold, assay and optimal interval remain unsettled (Sunakawa 2020, PMID 35050760). Meta-analysis supports activity in ctDNA-selected populations without replacing a randomized sequence comparison (da Silva 2024, PMID 39623250).

Resistance beyond one target

Resistance can be intrinsic (alteration present before treatment), adaptive (reversible signaling state) or acquired (selected genetic clone). A progressing lesion can differ from responding lesions.

Resistance pattern Best sampling strategy Potential response
Oligoprogression Imaging plus lesion review Local ablation while continuing systemic therapy
Widespread molecular escape Plasma ± tissue Change systemic target/backbone
Target loss Repeat tissue/plasma Avoid same target
Multiple subclones Plasma captures aggregate Combination or nonselective therapy

Reviews emphasize that ctDNA is a real-time evolutionary tool but prospective utility trials, not descriptive detection, must define when changing therapy improves survival (Patelli 2023, PMID 37436743; Parseghian 2019, PMID 31263029).

Assay-quality checklist

  • Adequate tumor fraction and recent specimen.
  • Validated coverage of RAS/BRAF and relevant fusions.
  • MMR/MSI method and discordance plan.
  • HER2 criteria stated by platform.
  • Germline implications separated from somatic result.
  • VUS excluded from treatment decisions.
  • Negative plasma reflexed to tissue when needed.
  • Turnaround time measured from order to treatment-ready result.

Open questions

  • What is the optimal first-line sequence for BRAF V600E after BREAKWATER? (Kopetz 2025, PMID 39863775)
  • Which dMMR patients need dual checkpoint therapy rather than PD-1 monotherapy? (André 2025, PMID 39874977)
  • Can ctDNA-guided anti-EGFR rechallenge improve overall survival versus standard late-line sequence? (da Silva 2024, PMID 39623250)
  • Which assay definition best predicts HER2 benefit across IHC, ISH and NGS? (Strickler 2023, PMID 37142372)
  • How should rare fusion screening be targeted without missing actionable cases? (Silvertown 2023, PMID 36194351)

References

  1. Morris VK, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678-700. PMID 36252154
  2. André T, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218. PMID 33264544
  3. Tabernero J, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39(4):273-284. PMID 33503393
  4. Strickler JH, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24(5):496-508. PMID 37142372
  5. Fakih MG, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;389(23):2125-2139. PMID 37870968
  6. Rossini D, et al. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. Eur J Cancer. 2023;184:106-116. PMID 36913832
  7. Parseghian CM, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243-249. PMID 30462160
  8. Venook AP, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017;317(23):2392-2401. PMID 28632865
  9. Andre T, et al. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024;391(21):2014-2026. PMID 39602630
  10. André T, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405(10476):383-395. PMID 39874977
  11. Le DT, et al. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer. 2023;186:185-195. PMID 37141828
  12. Kopetz S, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025;31(3):901-908. PMID 39863775
  13. Tabernero J, et al. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open. 2021;6(6):100328. PMID 34896698
  14. Sartore-Bianchi A, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738-746. PMID 27108243
  15. Kuboki Y, et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024;30(1):265-270. PMID 38177853
  16. Hong DS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531-540. PMID 32105622
  17. Silvertown JD, et al. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. Mol Diagn Ther. 2023;27(1):87-103. PMID 36194351
  18. Sartore-Bianchi A, et al. Application of histology-agnostic treatments in metastatic colorectal cancer. Dig Liver Dis. 2022;54(10):1291-1303. PMID 35701319
  19. Mur P, et al. Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1. Genome Med. 2023;15(1):85. PMID 37848928
  20. Topham JT, et al. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. J Clin Oncol. 2023;41(3):485-496. PMID 36007218
  21. Raghav K, et al. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). J Clin Oncol. 2023;41(3):472-478. PMID 36067452
  22. Sunakawa Y, et al. RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer. JCO Precis Oncol. 2020;4:898-911. PMID 35050760
  23. da Silva LFL, et al. Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis. J Gastrointest Cancer. 2024;56(1):28. PMID 39623250
  24. Patelli G, et al. Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer. Clin Cancer Res. 2023;29(22):4530-4539. PMID 37436743
  25. Parseghian CM, et al. Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clin Cancer Res. 2019;25(23):6899-6908. PMID 31263029